Q32 Bio: Oppenheimer slashes price target on mixed trial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Q32 Bio Inc. (QTTB) PT Lowered to $20 at Oppenheimer
December 11, 2024 6:37 AM ESTOppenheimer analyst Jay Olson lowered the price target on Q32 Bio Inc. (NASDAQ: QTTB) to $20.00 (from $80.00) while maintaining a Outperform rating.
The analyst comments "QTTB reported negative AD but positive AA results along with an update on clinical development plans for bempikibart. While... More
